American journal of therapeutics最新文献

{"title":"Apixaban-Induced Tongue and Extremity Angioedema: A Case Report.","authors":"Safa Souissi, Khouloud Berrim, Imen Aouinti, Fatma Zgolli, Sarrah Kastalli, Sihem El Aidli","doi":"10.1097/MJT.0000000000002152","DOIUrl":"10.1097/MJT.0000000000002152","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e344-e347"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148256995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topiramate-Associated Fanconi Syndrome, Hyponatremia, and Acute Kidney Injury: A Case Report.","authors":"Mikyung L Lee, Raxon White, David N Lee","doi":"10.1097/MJT.0000000000002166","DOIUrl":"10.1097/MJT.0000000000002166","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e329-e330"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148256991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical Appraisal of \"Continued versus Interrupted Oral Anticoagulation During Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation: A Meta-Analysis\".","authors":"Maryum Tahir, Iqra Akhtar, Muhammad H Javaid","doi":"10.1097/MJT.0000000000002151","DOIUrl":"10.1097/MJT.0000000000002151","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e341-e342"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salvage Therapy With Upadacitinib for Tofacitinib-Refractory Scarring Alopecia in an Asian Patient: Role of JAK1 Selective Inhibition.","authors":"Yu-Ting Gan, Shi Yan, Yi Liu, Feng-Lin Chen","doi":"10.1097/MJT.0000000000002060","DOIUrl":"10.1097/MJT.0000000000002060","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e360-e361"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness.","authors":"Timothy Nguyen, Kristine C Willett, Laura R Daly, Julia Junker, Oana Andreescu, Lorena Dima","doi":"10.1097/MJT.0000000000002147","DOIUrl":"10.1097/MJT.0000000000002147","url":null,"abstract":"<p><strong>Background: </strong>Motion sickness affects millions of people with common symptoms, including nausea and vomiting. Medications used for management of motion sickness since 1870 predominately have anticholinergics and antihistamines properties. For the past 40 years, there have been no advances in medication options for motion sickness until recently, a novel agent, tradipidant received the Food and Drug Administration approval for symptoms related to motion sickness.</p><p><strong>Mechanism of action, pharmacodynamics, and pharmacokinetics: </strong>Tradipitant is a selective neurokinin-1 (NK-1) receptor antagonist, blocking the actions of substance P, a neurotransmitter from the tachykinin family. It has high affinity for NK-1 receptors that are present throughout the emetic pathway. The 4 major metabolites of this drug (ie, M2, M3, M4, and M8) have shown a similar affinity to the NK-1 receptor as the parent drug. Pharmacokinetic data have revealed that tradipitant absorption is delayed when administered with food. The volume of distribution is 1956 L and is highly plasma protein bound (∼96%). The half-life is 34 hours. Tradipitant is predominately metabolized by CYP450-mediated pathways and through glucuronidation. Approximately 80% of excretion of tradipitant occurs in the feces.</p><p><strong>Clinical trials: </strong>Two phase 3 pivotal trials, Motion Syros (N = 365) and Motion Serifos (N = 316), randomized, double-blinded, placebo-controled, showed significant efficacy for tradipitant in preventing vomiting associated with motion sickness. In Motion Syros, tradipitant groups experienced significantly lower incidences of vomiting than placebo (170 mg tradipitant = 18.3%, 85 mg tradipitant = 19.5%, placebo = 44.3%). In Motion Serifos, 10.4% of the 170-mg tradipitant group and 18.3% of the 85-mg tradipitant group experienced vomiting, compared with 37.7% of the placebo group ( P = 0.00002 and P = 0.0014, respectively). The results of the 2 trials validated tradipitant as an effective NK-1 receptor antagonist for motion sickness prevention. The drug was well tolerated with a favorable safety profile and no serious adverse events.</p><p><strong>Therapeutic advance: </strong>Tradipitant works by blocking the NK-1 receptors found in the emetic pathway and it has been proven in pivotal trials effective for prevention of vomiting due to motion sickness. It reduces motion sickness symptoms in 2 phase 3 trials and offers a revolutionary new treatment option for people who experience motion sickness.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e324-e328"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147969760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes With Peptide Receptor Radionuclide Therapy in Patients With Pheochromocytoma/Paraganglioma: A Center of Excellence Experience.","authors":"Matthew T Gao, Rishi R Patel, Sanchay Jain, Joseph S Dillon, Chandrikha Chandrasekharan, Udhayvir S Grewal","doi":"10.1097/MJT.0000000000002149","DOIUrl":"10.1097/MJT.0000000000002149","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e342-e344"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148256988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjunctive Tofacitinib in Moderate-To-Severe Bullous Pemphigoid: A Single-Center Prospective Cohort Study.","authors":"Xiang-Yu Chen, Shi Yan, Hai-Zhen Hui, Ze Peng, Bing-Jun Shi","doi":"10.1097/MJT.0000000000002155","DOIUrl":"10.1097/MJT.0000000000002155","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e347-e349"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Right Side Accessory Pathway Mediated Cardiomyopathy Treated with Amiodarone: First Adult Case Report.","authors":"Anthony Costa, Ian Laxina, Fayaz Hakim, Khalil Kanjwal","doi":"10.1097/MJT.0000000000002161","DOIUrl":"10.1097/MJT.0000000000002161","url":null,"abstract":"<p><strong>Background: </strong>Right-sided accessory pathways can cause ventricular dyssynchrony through early right ventricular preexcitation, mimicking left bundle branch block and leading to reversible cardiomyopathy even without sustained tachycardia. Although catheter ablation is standard, pharmacologic reversal in adults has not been reported.</p><p><strong>Data sources: </strong>Single-patient case from a US community hospital. Literature review (PubMed/Embase) confirmed no previous adult cases of complete pharmacologic reversal.</p><p><strong>Main findings: </strong>A 44-year-old man with known Wolff-Parkinson-White presented with palpitations, dyspnea, chest pain, and syncope. Electrocardiogram showed right-sided preexcitation with left bundle branch block morphology. Echocardiography demonstrated left ventricular systolic function with ejection fraction (LVEF) 10%-15% with LV dilation. Coronary arteries were normal and no other cardiomyopathy etiologies were identified. The patient declined ablation. Amiodarone was initiated. Within 2 months, preexcitation resolved (loss of delta wave) and LVEF improved to 30%-35%. By 4 months, LVEF normalized to 60% with resolution of dilation. Amiodarone was discontinued and switched to flecainide.</p><p><strong>Limitations: </strong>No cardiac MRI performed (patient preference and rapid improvement); no extended ambulatory rhythm monitoring; and no formal electrophysiology study.</p><p><strong>Conclusions: </strong>Amiodarone-induced suppression of antegrade right-sided accessory pathway conduction can lead to complete reversal of severe dyssynchrony-mediated cardiomyopathy in adults when ablation is declined.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e330-e333"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148275667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do Not Treat a Sequencing Report: Therapeutic Stewardship in Endometrial Microbiome Testing.","authors":"Argyro Papadopoulou, Georgios Tournas, Panagiotis Antsaklis, Georgios Daskalakis, Ekaterini Domali","doi":"10.1097/MJT.0000000000002175","DOIUrl":"10.1097/MJT.0000000000002175","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e349-e350"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148275708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scropifav Antivenom Versus Supportive Care Alone in the Treatment of Pediatric Scorpion Envenomation.","authors":"Inbal Kestenbom, Shaked Bar-Moshe, Gidon Test, Or Kaplan, Tal Grupel, Michael Shilo, Natalya Bilenko, Michael Friger, Michal S Maimon, Dennis Scolnik, Miguel Glatstein","doi":"10.1097/MJT.0000000000002046","DOIUrl":"10.1097/MJT.0000000000002046","url":null,"abstract":"<p><strong>Background: </strong>Scorpion envenomation is a significant public health concern in specific regions and can have severe consequences in pediatric patients. The efficacy of antivenom treatment remains controversial.</p><p><strong>Objective: </strong>To compare the clinical course and outcomes of pediatric scorpion envenomation in patients receiving SCORPIFAV antivenom versus supportive care alone.</p><p><strong>Methods: </strong>We conducted a retrospective study of children aged 0-18 years presenting with grade ≥2 scorpion envenomation to the pediatric emergency department at Soroka University Medical Center, Israel, between 2014 and 2020. Clinical outcomes were compared between patients who received SCORPIFAV and those treated with supportive care alone.</p><p><strong>Results: </strong>A total of 194 children were included (median age: 3 years, interquartile range: 2-8 years); 125 received SCORPIFAV and 69 received supportive care only. Patients treated with SCORPIFAV required less sedation (10.3% vs. 23.4%, P = 0.02), less analgesia (53.3% vs. 81.3%, P < 0.001), and fewer antihypertensive medications (0% vs. 17.2%, P < 0.001). SCORPIFAV administration was associated with higher odds of requiring minimal additional treatment (OR = 2.568, 95% CI, 1.168-5.646, P = 0.019). No significant differences were found in pediatric intensive care unit admission rates or length of stay.</p><p><strong>Conclusions: </strong>In pediatric patients with grade ≥2 scorpion envenomation, SCORPIFAV use was associated with reduced need for sedatives, analgesics, and antihypertensive medications. These findings suggest that early administration of SCORPIFAV in the emergency setting may help attenuate the sympathetic response and reduce overall treatment intensity.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":"e285-e291"},"PeriodicalIF":3.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145766617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}